Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone

Phase 2

BAYER (BAYRY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

8 competitors in Prostate Cancer

CADLaglatimagene besadenovec

Phase 3

CASIPanzem® NCD

Phase 2

SNYCabazitaxel XRP6258

Phase 2

4503.TCP-461

Phase 2

BTAIBXCL701 plus Pembrolizumab

Phase 2

View Full Landscape

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT02097303

Last updated: 8/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma

bemdaneprocelPhase 3

Parkinsons Disease (PD)

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts